We're awaiting earnings from Pfizer this morning, which is simultaneously trying to acquire U.K. drugmaker AstraZeneca--in a deal that may cost it much more than the $106 billion it already offered. Orbitz is set to report earnings as well--after underperforming competitors Priceline and Tripadvisor, analysts are forecasting a loss. And Jim Cramer is charged up over one pick he's saying could catch fire in emerging markets.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux